157 related articles for article (PubMed ID: 25557290)
1. Identification of high-risk Dukes B colorectal cancer by microRNA expression profiling: a preliminary study.
Aslam MI; Venkatesh J; Jameson JS; West K; Pringle JH; Singh B
Colorectal Dis; 2015 Jul; 17(7):578-88. PubMed ID: 25557290
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of microRNA-21 as a biomarker in each Dukes' stage of colorectal cancer.
Fukushima Y; Iinuma H; Tsukamoto M; Matsuda K; Hashiguchi Y
Oncol Rep; 2015 Feb; 33(2):573-82. PubMed ID: 25421755
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers.
Kleist B; Meurer T; Poetsch M
Tumour Biol; 2017 Mar; 39(3):1010428317692246. PubMed ID: 28345467
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of PDCD4 expression and association with microRNA-21 in each Dukes' stage of colorectal cancer patients.
Horiuchi A; Iinuma H; Akahane T; Shimada R; Watanabe T
Oncol Rep; 2012 May; 27(5):1384-92. PubMed ID: 22267128
[TBL] [Abstract][Full Text] [Related]
5. Identification of a metastasis-specific MicroRNA signature in human colorectal cancer.
Hur K; Toiyama Y; Schetter AJ; Okugawa Y; Harris CC; Boland CR; Goel A
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663689
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
[TBL] [Abstract][Full Text] [Related]
7. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
Larsen AC
Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers.
Choi YW; Song YS; Lee H; Yi K; Kim YB; Suh KW; Lee D
Medicine (Baltimore); 2016 Apr; 95(15):e3321. PubMed ID: 27082577
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA profiling differentiates colorectal cancer according to KRAS status.
Mosakhani N; Sarhadi VK; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S
Genes Chromosomes Cancer; 2012 Jan; 51(1):1-9. PubMed ID: 21922590
[TBL] [Abstract][Full Text] [Related]
10. Relationship between
Proença MA; Biselli JM; Succi M; Severino FE; Berardinelli GN; Caetano A; Reis RM; Hughes DJ; Silva AE
World J Gastroenterol; 2018 Dec; 24(47):5351-5365. PubMed ID: 30598580
[TBL] [Abstract][Full Text] [Related]
11. Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer.
Michl M; Taverna F; Kumbrink J; Schiergens TS; Heinemann V; Engel J; Kirchner T; Neumann J
Virchows Arch; 2021 Apr; 478(4):695-705. PubMed ID: 33300106
[TBL] [Abstract][Full Text] [Related]
12. microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer.
Takahashi H; Takahashi M; Ohnuma S; Unno M; Yoshino Y; Ouchi K; Takahashi S; Yamada Y; Shimodaira H; Ishioka C
BMC Cancer; 2017 Nov; 17(1):723. PubMed ID: 29115941
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs associated with initiation and progression of colonic polyp: a feasibility study.
Aslam MI; Hussein S; West K; Singh B; Jameson JS; Pringle JH
Int J Surg; 2015 Jan; 13():272-279. PubMed ID: 25496852
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA Expression in
Lundberg IV; Wikberg ML; Ljuslinder I; Li X; Myte R; Zingmark C; Löfgren-Burström A; Edin S; Palmqvist R
Anticancer Res; 2018 Feb; 38(2):677-683. PubMed ID: 29374690
[TBL] [Abstract][Full Text] [Related]
15. Identification of microRNA-487b as a negative regulator of liver metastasis by regulation of KRAS in colorectal cancer.
Hata T; Mokutani Y; Takahashi H; Inoue A; Munakata K; Nagata K; Haraguchi N; Nishimura J; Hata T; Matsuda C; Murata K; Mizushima T; Doki Y; Mori M; Yamamoto H
Int J Oncol; 2017 Feb; 50(2):487-496. PubMed ID: 28000854
[TBL] [Abstract][Full Text] [Related]
16. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway.
Nosho K; Igarashi H; Nojima M; Ito M; Maruyama R; Yoshii S; Naito T; Sukawa Y; Mikami M; Sumioka W; Yamamoto E; Kurokawa S; Adachi Y; Takahashi H; Okuda H; Kusumi T; Hosokawa M; Fujita M; Hasegawa T; Okita K; Hirata K; Suzuki H; Yamamoto H; Shinomura Y
Carcinogenesis; 2014 Apr; 35(4):776-83. PubMed ID: 24242331
[TBL] [Abstract][Full Text] [Related]
17. Combined miRNA profiling and proteomics demonstrates that different miRNAs target a common set of proteins to promote colorectal cancer metastasis.
Torres S; Garcia-Palmero I; Bartolomé RA; Fernandez-Aceñero MJ; Molina E; Calviño E; Segura MF; Casal JI
J Pathol; 2017 May; 242(1):39-51. PubMed ID: 28054337
[TBL] [Abstract][Full Text] [Related]
18. Differential microRNA expression profiling in primary tumors and matched liver metastasis of patients with colorectal cancer.
Li W; Chang J; Tong D; Peng J; Huang D; Guo W; Zhang W; Li J
Oncotarget; 2017 May; 8(22):35783-35791. PubMed ID: 28415758
[TBL] [Abstract][Full Text] [Related]
19. How can we identify new biomarkers for patients with for lung metastasectomy in colorectal cancer.
Renaud S; Falcoz PE
Future Oncol; 2015; 11(15):2109-11. PubMed ID: 26235176
[No Abstract] [Full Text] [Related]
20. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer.
Ma Y; Zhang P; Wang F; Zhang H; Yang J; Peng J; Liu W; Qin H
Gut; 2012 Oct; 61(10):1447-53. PubMed ID: 22052060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
